Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus WYMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus WYMOX.
OMNIPEN (AMPICILLIN) vs WYMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and peptidoglycan cross-linking.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for 7-14 days; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in adults with normal renal function. In neonates, it may be prolonged to 2-4 hours; in renal impairment, half-life can extend significantly (up to 8-20 hours in severe impairment).
0.7-1.4 hours (mean ~1 hour) in adults with normal renal function; prolonged to 2-6 hours in anuria.
Renal excretion accounts for approximately 90% of elimination, primarily via tubular secretion and glomerular filtration. Biliary/fecal excretion is minimal, <10%.
Renal: 60-70% unchanged via glomerular filtration and tubular secretion; biliary: <5%; fecal: <5%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic